StemCell Therapy

Arthritis pain can lead to a number of debilitating symptoms that patients will want to try and avoid.

The condition can make life more difficult when carrying out simply, everyday tasks.

It's crucial that if you develop signs of arthritis, you speak to a doctor as soon as possible to try and find a treatment to relieve your pain.

One of the best ways to avoid arthritis pain is to eat more onions, it's been claimed.

READ MORE: Arthritis pain - the best vegetable to lower your risk of joint pain

"While the cure for arthritis eludes medical science, there are many potent treatments for the condition," it said.

"Chief among these are avoiding foods that exacerbate joint pain and eating foods that reduce it.

"Loaded with immune-boosting properties, garlic and onions are the superhero duo of the produce section.

"Studies have shown that those who eat foods in the allium family, such as garlic and onions, exhibit fewer signs of osteoarthritis and joint pain."

Common arthritis symptoms include joint pain, inflammation, and restricted movement.

There are two key types of arthritis in the UK; osteoarthritis and rheumatoid arthritis.

Osteoarthritis is the most common type of arthritis to be diagnosed in the UK - around nine million people are believed to have osteoarthritis.

Rheumatoid arthritis, meanwhile, is an auto-immune disease that has been diagnosed in about 400,000 individuals.

Follow this link:
Arthritis pain - the 90p 'superhero' vegetable you should add to your diet for joint pain - Express

About one in three people between ages 18 and 64 have some type of arthritis.

This common joint disease can wreak havoc on everyday life, but there are some ways to protect yourself.

Its coverage affecting your health.

Running, jumping and climbing stairs or mountains, your joints take a lot of abuse over time. It can lead to osteoarthritis and its not just a disease for the old.

Were seeing arthritis at an earlier age, not only in the knees, but shoulders, really everywhere. Its becoming an epidemic of sorts, said Dr. Matthew Pombo, MD, Emory Orthopedics and Spine Center.

So you can safe guard your joints?

First ditch the high heels as they put pressure on your knees and feet. A three inch heel stresses your foot seven times more than a one inch heel.

You might also want to scrap the sodas. A Harvard study found that men with osteoarthritis who drank more sugary carbonated drinks reported worse symptoms.

You might also want to get active, but ramp it up slowly and be careful of injuries.

We also have a lot of younger people participating in sports and we know that prior injury leads to post-traumatic arthritis, said Dr. Pombo.

Low impact activities such as walking, swimming and biking are best and extra weight is one of the biggest culprits for arthritis pain.

Every additional pound you gain puts four times the stress on your knees.

Research shows that losing as few as eleven pounds cuts your risk for osteoarthritis by 50% with ways to protect your joints.

See the original post:
Your Health: How to protect your joints from arthritis - YourErie

Postpartum Arthritis: What to do if you are suffering from joint pain after delivery Pledge Times

No Result

View All Result

Let us know the causes of arthritis after delivery and what treatment options are available.

Arthritis after pregnancyArthritis can be troublesome at any age and the disease affects more women than men. Complaints of arthritis may increase after pregnancy, and some women continue to have arthritis pain after delivery. Arthritis can occur after delivery in the wrist, hands, ankles and feet.Cause of postpartum arthritisArthritis after delivery is called postpartum arthritis. The following reasons of arthritis of the child can be:Women who have arthritis before pregnancy can be relieved during pregnancy. Most autoimmune diseases such as rheumatoid arthritis or psoriatic arthritis disappear during pregnancy. This is due to antibodies and immune responses. Symptoms of arthritis may return after delivery.The immune system usually becomes strong after pregnancy. Any pre-allergic or autoimmune diseases such as rheumatoid arthritis can cause lupus due to the hyperactivity of the immune system.Age, obesity, jeans, lack of physical activity, smoking, infection and lack of nutrients in the diet can also cause arthritis or joint pain after pregnancy.Treatment of postpartum arthritisTell a doctor if you are complaining of joint pain or arthritis after delivery. Doctors can give treatment to reduce pain, reduce damage to joints. For this, you will have to go to the doctor periodically for a checkup.Apart from this, it is also very important to have a balanced and nutritious diet. Take calories, burn fat. If you have gained weight after delivery, weight loss can also relieve joint pain. When the weight is high, there is pressure on the erect joints especially on the axes and knees. Overweight increases the risk of arthritis.Being physically active can help reduce pain and improve mood. It also protects against long-term conditions like diabetes, high BP.

Conceive with arthritisThe 2011 study included approximately 74,000 pregnant women. All these women were suffering from Rheumatoid Arthritis and were having difficulty convalescing like normal women. About twenty five percent of these women were trying to conceive for about a year before becoming pregnant. Among women who did not suffer from rheumatoid arthritis, this figure was only sixteen percent.It is very important to control arthritis for at least 3 to 6 months before becoming pregnant.

.

Enneagram 7. The multi-tasker. Growing one step closer every day to leaving my legacy.

No Result

View All Result

Excerpt from:
Postpartum Arthritis: What to do if you are suffering from joint pain after delivery - Pledge Times

What did Bye set out to achieve?

According to Bye, numerous studies show that high-intensity interval training is much more effective for improving endurance than moderate intensity training.

"This is true regardless if you're sick or healthy, young or old. We wanted to see if patients with arthritis could handle high intensity training and see the same positive effects," said Bye.

After ten weeks of hard training on a spinning bike twice a week, Bye saw no adverse effects on her study's participants, a group of women with arthritis.

"Rather, we saw a tendency for there to be less inflammation, at least as measured by the inflammation marker CRP, and the participants of the study experienced a solid increase in maximum oxygen intake, meaning that they reduced their risk of cardiovascular disease," Bye said.

The participants also saw a small reduction in BMI, body fat percent and waist measurement, as well as an increase in muscle mass as a result of the training period.

The participants warmed up for ten minutes at 70 per cent of their maximum pulse, and then did four repetitions of high intensity (85-95 percent of max pulse) four-minute intervals.

The break between each interval was about three minutes, at 70 percent of max pulse. The total work-out session lasted about 35 minutes.

"The women who participated in the study found this to be a good, effective method of training, and are mostly very motivated to continue because of the progress they've seen," Bye concluded.

The NHS issues important advice when it comes to trying out different forms of exercise.

"If a particular activity causes your joints to become warm and swollen, or it causes severe pain, then stop and rest," says the health body.

If it does not cause problems, then it is usually fine to continue, notes the health site.

It adds: "If a particular activity always causes a flare-up, it's best to avoid it and find an alternative."

Read the original post:
Rheumatoid arthritis treatment: The fast workout that may provide pain relief - Express

Global Arthritis Therapeutics Marketwas valued USD XX Bn in 2018 and is expected to reach US$ XX Bn by 2026, at CAGR of 4.8 % during forecast period of 2019 to 2026.

REQUEST FOR FREE SAMPLE REPORT:https://www.maximizemarketresearch.com/request-sample/36112

Global Arthritis Therapeutics MarketThe report study has analyzed revenue impact of COVID -19 pandemic on the sales revenue of market leaders, market followers and market disrupters in the report and same is reflected in our analysis.Arthritis is an inflammatory disorder affecting the joints cause redness, stiffness, resulting in pain and swelling in the joints. More than 100 categories of arthritis are affecting the global population. The most common arthritis conditions are psoriatic arthritis, rheumatoid arthritis, and osteoarthritis. The osteoarthritis affects a majority of the geriatric population, in severe joint pain and affecting their movement. Psoriatic Arthritis therapeutics contains drugs that help to reduce pain and inflammation.

Global Arthritis Therapeutic Market Drivers and RestrainsThe significant growth of the global arthritis therapeutics market is credited to investments in research & development, strong product pipeline, increasing patient pool suffering from arthritis. Furthermore, rise in the geriatric population is another factor fueling the growth of the global arthritis therapeutics market. Patients gone under treatment with Disease-Modifying Antirheumatic Drugs (DMARDs) are unsatisfied because of poor therapeutic benefits. The dominance of rheumatoid arthritis globally, the launch of novel therapeutic agents, and favorable reimbursement policies for high-cost treatment products are the factors that boost the growth of global arthritis therapeutics market. In 2016, the International Federation of Psoriasis Association (IFPA) states that more than 125 Mn people were affected with psoriasis. It is estimated that between 11% and 32% of patients with psoriasis incline to develop psoriatic arthritis. Furthermore, nearly 52.2 million adults suffered from arthritis in U.S. alone in 2015. Developments in diagnostics and healthcare infrastructure in developing countries are projected to witness an increased number of diagnosed patients.

Manufacturers in the Arthritis Therapeutic are focusing on competitive pricing as the strategy to capture significant market share. Moreover, strategic mergers and acquisitions and technological innovations are also the key focus areas of the manufacturers.

Global Arthritis Therapeutic Market Segmentation AnalysisBy Arthritis Therapeutic Market is segmented into Psoriatic Arthritis, Rheumatoid Arthritis, Osteoarthritis, Gout and Others. Rheumatoid Arthritis and Psoriatic Arthritis segment is expected to exhibit highest global market share at a CAGR of xx% over forecast period. Increasing occurrence of arthritis diseases globally, is likely to drive key players to develop novel therapeutics treatment for the disease. Strong research and development by key companies supported by huge investments is projected to drive the global arthritis therapeutics market. In 2018, according to the WHO statistics 9.9 % of men AND 18.1 % of women over the age of 60 suffered from osteoarthritis, symptomatic, worldwide. About 80 % of those with osteoarthritis have limitations in movement, and 25 % of women over the age of 60 suffered from symptomatic osteoarthritis, globally.

Global Arthritis Therapeutic Market Regional AnalysisThe Global Arthritis Therapeutic Market has been classified into five major regions: North America, Europe, Asia Pacific, Latin America, and the Middle East Africa. North America dominated the global arthritis therapeutics market, followed by Europe. Because of a large patient pool suffering from arthritis diseases, like osteoarthritis, rheumatoid arthritis and other conditions. Advantageous reimbursement policies, launching of novel biologics drugs, well-defined regulatory framework, and availability of biosimilars are boost up the market growth in the region. Furthermore, the presence of key players in the region and a strong product pipeline for arthritis treatment are projected to drive the arthritis therapeutics market in the region. This can be ascribed to awareness about arthritis, presence of key players, growing patient pool, favorable reimbursement policies, and availability of biosimilar and biologics arthritis drugs in the region.

The objective of the report is to present comprehensive analysis of Global Arthritis Therapeutic Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of industry with dedicated study of key players that includes market leaders, followers and new entrants by region. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors by region on the market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give clear futuristic view of the industry to the decision makers. The report also helps in understanding Global Arthritis Therapeutic Market dynamics, structure by analyzing the market segments, and project the Global Arthritis Therapeutic Market size. Clear representation of competitive analysis of key players by Arthritis Therapeutic Type, price, financial position, product portfolio, growth strategies, and regional presence in the Global Arthritis Therapeutic Market make the report investors guide.Scope of the Global Arthritis Therapeutic Market

Global Arthritis Therapeutic Market, by Type

Psoriatic Arthritis Rheumatoid Arthritis Osteoarthritis Gout OthersGlobal Arthritis Therapeutic Market, by Drug Class

TNF Inhibitors Interleukin Inhibitors NSAIDs Corticosteroids Xanthine Oxidase Inhibitors OthersGlobal Arthritis Therapeutic Market by Route of Administration

Oral Parenteral TopicalGlobal Arthritis Therapeutic Market, by Distribution Channel

Hospital Pharmacies Retail Pharmacies Online PharmaciesGlobal Arthritis Therapeutic Market, by Region

Asia Pacific North America Europe Latin America Middle East AfricaGlobal Arthritis Therapeutic Market, Major Players

Pfizer Inc. Bristol Myers Squibb Abbvie Inc. Astrazeneca Pharma Ucb Pharma Genentech Janssen Pharmaceutical Immunex Corp. Medac Pharma Boehringer Ingelheim Novartis, Biogen Eli Lilly And Company Astellas Pharma Mallinckrodt Roche Vertex Pharmaceutical

Browse Full Report with Facts and Figures Report at:https://www.maximizemarketresearch.com/market-report/global-arthritis-therapeutic-market/36112/

About Us:

Maximize Market Research provides B2B and B2C market research on 20,000 high growth emerging technologies & opportunities in Chemical, Healthcare, Pharmaceuticals, Electronics & Communications, Internet of Things, Food and Beverages, Aerospace and Defense and other manufacturing sectors.

Contact info:

Name: Vikas Godage

Organization: MAXIMIZE MARKET RESEARCH PVT. LTD.

Email: [emailprotected]

Contact: +919607065656/ +919607195908

Website:www.maximizemarketresearch.com

Continued here:
Global Arthritis Therapeutic Market: Industry Analysis and forecast (2019 to 2026) - Galus Australis

LOS ANGELES, Aug. 31, 2020 /PRNewswire/ -- Arrow Organics offers a wide range of premium CBD products. In an industry full of new competition and subpar transparency, Arrow Organics doubled down on science based CBD by pairing up with Alex Laughlin, a Biology PhD candidate from Cornell University. "After reviewing countless scientific case studies on CBD's efficacy in helping arthritis pains and sports injuries, we sought out the help of Alex Laughlin, MSc to carefully choose which formulas would give our customers the best relief," said Luke Paschal, CEO of Arrow Organics.

Arrow Organics recently launched two new topical CBD rubs formulated to provide relief from sore and injured muscles and joints by reducing inflammation to affected areas. "The ingredients in both the Intensive Relief Rub and Athletic Freeze Rub were specifically chosen for their ability to ease arthritis pain and muscle aches. "Coupling CBD's powerful effects with the specific ingredients of both creams have been shown to greatly reduce pain in various forms," said Laughlin.

Slow moving regulation hands the responsibility off to consumers on choosing the correct CBD company. The consumer must be educated on what types of CBD they're buying, if the lab reports are consistent with labeling, and how to properly use CBD. You can visit Arrow Organics website to view lab reports and get educated on CBD. "We happily welcome any questions about CBD, please feel free to reach out through our website or through email ([emailprotected])" Paschal.

Arrow Organics is currently offering free shipping nationwide as well as 20% off your next order with code "ARROW20".

Photo(s):https://www.prlog.org/12836149

Press release distributed by PRLog

SOURCE Arrow Organics

Read the original here:
Arrow Organics Commits to Science Based Full Spectrum Blends By Partnering with Ivy League Scientist - PRNewswire

Rheumatoid Arthritis Therapeutics Market Scenario 2020-2028:

The analysis of the market provides the global market dynamics and trends of the Rheumatoid Arthritis Therapeutics Market. The market study offers current and future outlook of the Rheumatoid Arthritis Therapeutics Market over the forecast period.

The analysis of the market provides an exhaustive overview with detailed growth scenarios and market potential with accurate market drivers and maximum forecast precision. The report comprises of exclusive and important factors that are likely to have a major impact on the Rheumatoid Arthritis Therapeutics Market throughout the forecast period. This study of the market includes a thorough and considerable amount of addition, which will help new entrants in the most comprehensive manner for better understanding. Click here to get sample of the premium report: https://www.quincemarketinsights.com/request-sample-68410?utm_source= SNG/KK

The analysis of the market commences with the executive summary of the Rheumatoid Arthritis Therapeutics Market study, which includes key findings and key information on the market. It includes market value share for the foremost segments in the Rheumatoid Arthritis Therapeutics Market. In addition, this section includes demand-side trends, supply-side trends, and recommendations for the Rheumatoid Arthritis Therapeutics Market.

Market Segmentation-

Based on the study the Rheumatoid Arthritis Therapeutics Market is segmented by By Molecule Type (Biopharmaceuticals (Biologics, Biosimilars), Pharmaceuticals), By Sales Channel (Prescription, OTC) This information can lead to a focused approach leading to better opportunities being found.

Based on the region, the Rheumatoid Arthritis Therapeutics Market has been categorized into North America, Europe, Asia Pacific, Middle East, and the Rest of the world. It also consists of detailed information regarding developments, key market trends, and market analysis in the Rheumatoid Arthritis Therapeutics Market based on region. The North America and Western Europe regions are estimated to register a stable demand during the forecast period with market recovery from recent slowdowns.

North America region includes the US, Canada, and Mexico. The US is estimated to dominate this market with a sizeable share followed by Canada, and Mexico. The industrial sector is a major contributor to the US and Canada economies overall. Hence, the supply of advanced materials in production activities is critical to the overall growth of industries in this region.

Get ToC for the overview of the premium report https://www.quincemarketinsights.com/request-toc-68410?utm_source=SNG/KK

The Rheumatoid Arthritis Therapeutics Market report examines the potential of the market in the key geographical region:

Speak to analyst before buying this report https://www.quincemarketinsights.com/enquiry-before-buying-68410?utm_source=SNG/KK

Competitive Analysis

The report includes a comprehensive list of all the leading manufacturers in the Rheumatoid Arthritis Therapeutics Market, along with detailed information about each company, which includes the company overview, revenue share, strategic overview, and recent company developments. Market players featured in this report include AbbVie;Boehringer Ingelheim GmbH;Novartis AG; Regeneron Pharmaceuticals, Inc.;Pfizer, Inc.; Bristol-Myers Squibb Company;F. Hoffmann-La Roche Ltd.;UCB S.A.; Johnson & Johnson Services, Inc.; andAmgen, Inc.. A detailed view of the competitive landscape covers future capabilities, key mergers & acquisitions, new product releases, new product innovations, etc.

Reasons why you should buy this report:

ABOUT US:

QMI has the most comprehensive collection of market research products and services available on the web. We deliver reports from virtually all major publications and refresh our list regularly to provide you with immediate online access to the worlds most extensive and up-to-date archive of professional insights into global markets, companies, goods, and patterns.

Contact:Quince Market Insights

Office No- A109

Pune, Maharashtra 411028

Phone: APAC +91 706 672 4848 / US +1 208 405 2835 / UK +44 1444 39 0986

Email: [emailprotected]

Web: https://www.quincemarketinsights.com

View original post here:
Rheumatoid Arthritis Therapeutics Market : Opportunities, Demand and Forecasts, 2020-2028 - StartupNG

NORTH CHICAGO, Ill., Aug. 25, 2020 /PRNewswire/ -- AbbVie(NYSE: ABBV) today announced that it has submitted an application for a new indication to the U.S. Food and Drug Administration (FDA) for RINVOQ (upadacitinib; 15 mg, once daily), a selective and reversible JAK inhibitor, for the treatment of adult patients with active ankylosing spondylitis. AbbVie also submitted an application to the European Medicines Agency (EMA) for RINVOQ earlier this year for the treatment of adult patients with active ankylosing spondylitis who have responded inadequately to conventional therapy.

"Ankylosing spondylitis is a debilitating disease that can cause severe pain, restricted mobility and lasting structural damage. With limited treatment options, innovation is crucial to help more patients living with active ankylosing spondylitis reach their treatment goals," said Michael Severino, M.D., vice chairman and president, AbbVie. "RINVOQ has the potential to improve care by helping to provide disease control, addressing pain and improving function. We look forward to working with regulatory authorities and hope to bring this important treatment option to patients."

The applications to the FDA and EMA are supported by data from SELECT-AXIS 1, a Phase 2/3 study in which RINVOQ demonstrated significant improvements in signs and symptoms in patients with active ankylosing spondylitis.1 In this study, twice as many patients receiving RINVOQ (52 percent) met the primary endpoint of Assessment of SpondyloArthritis International Society (ASAS) 40 response versus placebo (26 percent) at week 14 (p<0.001).1 The safety profile of RINVOQ in ankylosing spondylitis was consistent with previously reported studies across therapeutic areas, including rheumatoid arthritis, atopic dermatitis and psoriatic arthritis, with no new significant safety risks detected.2-4

Ankylosing spondylitis is a chronic, progressive, inflammatory musculoskeletal disease impacting more than five million people worldwide.5,6 The range of symptoms pose significant physical, psychological and economic burden on individuals impacted by the disease.5,7-9

About RINVOQ (upadacitinib)

Discovered and developed by AbbVie scientists, RINVOQ is a selective and reversible JAK inhibitor that is being studied in several immune-mediated inflammatory diseases.10-17 In August 2019, RINVOQ received U.S. FDA approval for adult patients with moderately to severely active rheumatoid arthritis who have had an inadequate response or intolerance to methotrexate. In December 2019, RINVOQ was approved by the European Commission for the treatment of adult patients with moderate to severe active rheumatoid arthritis who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. The approved dose for RINVOQ in rheumatoid arthritis is 15 mg. Phase 3 trials of RINVOQ in psoriatic arthritis, rheumatoid arthritis, axial spondyloarthritis, Crohn's disease, atopic dermatitis, ulcerative colitis and giant cell arteritis are ongoing.12-17 Use of RINVOQ in ankylosing spondylitis is not approved and its safety and efficacy have not been established by regulatory authorities.

Important Safety Information about RINVOQ (upadacitinib)18

RINVOQ is a prescription medicine used to treat adults with moderate to severe rheumatoid arthritis in whom methotrexate did not work well or could not be tolerated. It is not known if RINVOQ is safe and effective in children under 18 years of age.

What is the most important information I should know about RINVOQ?RINVOQ is a medicine that can lower the ability of your immune system to fight infections. You should not start taking RINVOQ if you have any kind of infection unless your healthcare provider (HCP) tells you it is okay.

What should I tell my HCP BEFORE starting RINVOQ?Tell your HCP if you:

Tell your HCP about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements. RINVOQ and other medicines may affect each other, causing side effects.

Especially tell your HCP if you take:

Ask your HCP or pharmacist if you are not sure if you are taking any of these medicines.

What should I tell my HCP AFTER starting RINVOQ?Tell your HCP right away if you:

What are the common side effects of RINVOQ?These include: upper respiratory tract infections (common cold, sinus infections), nausea, cough, and fever. These are not all the possible side effects of RINVOQ.

RINVOQ is taken once a day with or without food. Do not split, break, crush, or chew the tablet. Take RINVOQ exactly as your HCP tells you to use it.

This is the most important information to know about RINVOQ. For more information, talk to your HCP.

You are encouraged to report negative side effects of prescription drugs to the FDA. Visit http://www.fda.gov/medwatch or call 1-800-FDA-1088.

If you are having difficulty paying for your medicine, AbbVie may be able to help. Visit AbbVie.com/myAbbVieAssist to learn more. Please click here for theFull Prescribing InformationandMedication Guide. Globally, prescribing information varies; refer to the individual country product label for complete information.

About AbbVie in Rheumatology

For more than 20 years, AbbVie has been dedicated to improving care for people living with rheumatic diseases. Our longstanding commitment to discovering and delivering transformative therapies is underscored by our pursuit of cutting-edge science that improves our understanding of promising new pathways and targets in order to help more people living with rheumatic diseases reach their treatment goals. For more information on AbbVie in rheumatology, visit https://www.abbvie.com/our-science/therapeutic-focus-areas/immunology/immunology-focus-areas/rheumatology.html.

About AbbVie

AbbVie's mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people's lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology, in addition to products and services across its Allergan Aesthetics portfolio. For more information about AbbVie, please visit us atwww.abbvie.com. Follow @abbvie on Twitter,Facebook,Instagram,YouTubeandLinkedIn.

Forward-Looking Statements

Some statements in this news release are, or may be considered, forward-looking statements for purposes of the Private Securities Litigation Reform Act of 1995. The words "believe," "expect," "anticipate," "project" and similar expressions, among others, generally identify forward-looking statements. AbbVie cautions that these forward-looking statements are subject to risks and uncertainties that may cause actual results to differ materially from those indicated in the forward-looking statements. Such risks and uncertainties include, but are not limited to, failure to realize the expected benefits from AbbVie's acquisition of Allergan plc ("Allergan"), failure to promptly and effectively integrate Allergan's businesses, competition from other products, challenges to intellectual property, difficulties inherent in the research and development process, adverse litigation or government action, changes to laws and regulations applicable to our industry and the impact of public health outbreaks, epidemics or pandemics, such as COVID-19. Additional information about the economic, competitive, governmental, technological and other factors that may affect AbbVie's operations is set forth in Item 1A, "Risk Factors," of AbbVie's 2019 Annual Report on Form 10-K, which has been filed with the Securities and Exchange Commission, as updated by its subsequent Quarterly Reports on Form 10-Q. AbbVie undertakes no obligation to release publicly any revisions to forward-looking statements as a result of subsequent events or developments, except as required by law.

References:

View original content:http://www.prnewswire.com/news-releases/abbvie-submits-regulatory-application-to-fda-for-rinvoq-upadacitinib-for-the-treatment-of-adults-with-active-ankylosing-spondylitis-301117875.html

SOURCE AbbVie

See the article here:
AbbVie Submits Regulatory Application to FDA for RINVOQ (upadacitinib) for the Treatment of Adults with Active Ankylosing Spondylitis - BioSpace

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Psoriatic Arthritis Therapeutics Market market.

Trusted Business Insights presents an updated and Latest Study on Psoriatic Arthritis Therapeutics Market Market 2019-2029. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Psoriatic Arthritis Therapeutics Market market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Global Psoriatic Arthritis Therapeutics Market Analysis Trends, Applications, Analysis, Growth, and Forecast to 2028 is a recent report generated by Trusted Business Insights. The global Psoriatic Arthritis Therapeutics market report has been segmented on the basis of drug, diseases type, and region.

Request Covid 19 Impact

Global Psoriatic Arthritis Therapeutics Market: Overview

Psoriatic arthritis (PsA) is a type of chronic disease, characterized by inflammation in the joints and skin. This disease is progressive category of diseases that may worsening over time. If left untreated, this psoriatic arthritis may lead to joint damage permanently. It is characterized by potential involvement of diverse tissues, including, enthesitis, peripheral and axial joints, skin & nail disease, and dactylitis. The treatment of PsA includes the use of a variety of interventions that act as an agent for the treatment of patients with other forms of inflammatory arthritis, such as rheumatoid arthritis (RA), spondyloarthritis and others.

Global Psoriatic Arthritis Therapeutics Market: Dynamics

Increasing number of cases of psoriatic arthritis especially in elderly population is a key factor expected to drive the growth of the global market over the forecast period. In addition, rising awareness about psoriatic arthritis treatment among the healthcare professionals and increasing elderly population. The above mentioned are some of the other factors expected to drive growth revenue of the global market. However, high cost of the drugs and treatment, entry of biosimilar drug in the market, and lack of standardization tools for diagnosis and treatment. These are some of the major factors expected to hamper growth of the target market to a certain extent.

Global Psoriatic Arthritis Therapeutics Market: Segment Analysis

Among the drug type segments, Nonsteroidal anti-inflammatory drug is estimated to account for majority of revenue share in the global market. This is due to, rising prescribing of NSAID drugs for patients, in order to pain and morning stiffness, controlling swelling, and to improve range of motion to joints.

Among the diseases type segments, symmetric psoriatic arthritis is estimated to hold highest revenue and register highest CAGR over the forecast period, due to increasing number of cases of affecting several joints in pairs on both sides of your body. It may damage joints over time, that can lead to limited movement and function of body.

Global Psoriatic Arthritis Therapeutics Market: Trends

The established players are adopting various growth strategies such as partnership, collaboration, mergers, new product launch etc., in order to cater the growing demand for Psoriatic Arthritis Therapeutics globally. In addition, the prominent players are collaborating with local player in order to form string value and supply chain. The aforementioned are some of the current key trend witnessed in the target market.

Global Psoriatic Arthritis Therapeutics Market: Regional Analysis

In 2019, the markets in North America estimated to account for highest market revenue share in the target market over the forecast period. This is primarily attributed to, increasing incidences of psoriatic arthritis. According to RheumatoidArthritis.org, which is a non-profit team of healthcare professionals around 85% of individuals living with psoriatic arthritis in US. The markets in Asia Pacific accounted for highest CAGR over the forecast period, owing to increasing prevalence and incidences in the temperate zones in the region, and growing healthcare expenditure. In addition, higher demand and increased rate of adoption of biologic drugs in countries such as Australia & New Zealand, are projected to drive the psoriatic arthritis therapeutics market in Asia Pacific region.

Global Psoriatic Arthritis Therapeutics Market Segmentation:

Segmentation by drug:

Nonsteroidal anti-inflammatory drug (NSAID)Disease-modifying antirheumatic drug (DMARD)Biologic drugEnzyme inhibitor

Segmentation by diseases type:

Asymmetric Psoriatic ArthritisSymmetric Psoriatic ArthritisDistal Interphalangeal Predominant (Dip) Psoriatic ArthritisSpondylitisArthritis Mutilans

Looking for more? Check out our repository for all available reports on Psoriatic Arthritis Therapeutics Market in related sectors.

Quick Read Table of Contents of this Report @ Global Psoriatic Arthritis Therapeutics Market 2020 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

Visit link:
Global Psoriatic Arthritis Therapeutics Market Analysis, Drivers, Restraints, Opportunities, Threats, Trends, Applications, And Growth Forecast To...

Despite their ability to create matter out of thin air, algae and cyanobacteria have long been neglected by the biotech industry. Recently, however, they have started to gain traction in new market niches.

In the center of Paris, just across from Marie Curies old laboratory, Pierre Crozet, Associate Professor at Sorbonne University, studies photosynthesis. His research focuses on making microalgae easier to engineer and thus more appealing to the industry. [Microalgae] are photosynthetic, and quite efficient at it, but require much less space or nutrients than land plants, he told me.

The idea that new technologies should serve sustainability has started taking root in society. Using photosynthetic microbes for biotech applications appears to be a no-brainer. Algae grow biomass literally out of thin air, only needing water, carbon dioxide, and inorganic nutrients. Many grow on seawater and in lands not suitable for agriculture.

Today, we are managing quite well in transforming algae. I would thus not consider it particularly difficult, says Crozet, pointing out that, nowadays, obtaining a new strain of algae using genetic engineering takes just weeks. So, technically, they should be able to effectively replace bacteria and yeast, which generally require more complex growth facilities as well as the input of a sugar source in order to be able to generate any product.

However, algae have historically not been considered a good alternative to yeast and bacteria because of their slower growth rate. In addition, the crash of many algae biofuel companies about a decade ago dealt a blow to the field that it still has trouble recovering from.

The early 2010s saw several startups forming to produce biofuels, mainly in the US. Many claimed to be close to offering algal biofuel at competitive market prices. Sapphire Energy, Solazyme, and Algenol, among others, received significant public and private investments and built up high expectations. But due to technological challenges and the drop in oil prices between 2015 and 2016, no product became commercially viable and these businesses either went bankrupt or had to radically change their focus.

The [challenge] of algae and cyanobacteria comes down to their slow growth and the cost of production, says Hugh Goold, Research Scientist at the NSW Department of Primary Industries, Australia. According to Goold, the resources required to keep photosynthesis going is very high, meaning they dont replicate as quickly as the bacteria and yeast commonly used in biotech applications.

Bacteria and yeast have been optimized for many years in biotech applications such as producing commodity chemicals as well as high-value compounds such as pharmaceuticals, meaning that photosynthetic organisms can no longer compete with these applications. Investors have to know that you are going to produce a product cheaper than other people can. It isnt worthwhile to produce something in algae instead of E. coli just because, said Goold.

Despite this challenge, algae and cyanobacteria have started to get interest from new market niches where they could offer key advantages over traditional bioproduction methods.

Microalgae capture sunlight using pigments of vibrant colors, such as chlorophylls, carotenoids, and phycocyanin. In particular, the algae spirulina and chlorella found their way to the market a long time ago as food supplements and food colorants. Algae are also an excellent source of protein, which opens up a lot of opportunities in the production of meat analogs and vegan food in general.

Unilever, a massive producer of food and other consumer goods, has seen the nutritional potential of microalgae, partnering with UK-based company Algenuity in July. Algae are a source of high-quality plant-based protein, said Manfred Aben, Vice President of Science & Technology at Unilever. These products will appeal to a variety of consumers; for vegans and vegetarians but also for flexitarians and meat-eaters looking to reduce their consumption of animal products.

Within the food and beverage sector, the opportunities for microalgae-based ingredients are strong and tangible, explained Andrew Spicer, CEO of Algenuity. We do anticipate applications for microalgae-based ingredients in markets other than food and beverages where similar drivers around sustainability, plant-based, and natural sources of ingredients are equally strong.

Last year, the Dutch food and biochemical company Corbion announced a similar partnership with Nestl, signaling that big players in the food industry are starting to increasingly recognize the potential value of algae products. Other companies gaining traction in the field are Algama in France seeking to provide meat alternatives, and AlgaEnergy in Spain producing food and feed as well as cosmetics and fertilizers from algae.

In 2011, Renana Krebs graduated from the Shenkar College of Engineering, Design, and Art in Tel Aviv with a degree in fashion. While working for fashion brands, she realized the huge impact the industry has on the environment. Clothes and textiles manufacturing accounts for 10% of global carbon emissions and 20% of wastewater. Looking for alternative solutions, Krebs teamed up with her father and founded Algalife, a German-Israeli company offering algae-based fibers and textiles.

Algalife stands for a better planet and a better fashion industry. We provide and enable the opportunity for everyone to make better choices, for a healthy, sustainable well-being, Krebs told me. The company collaborates with fashion brands that are willing to learn and adjust their practices to include the green fibers, and even pay more for sustainable solutions.

Renana Krebs considers algae as one of the most influential resources for sustainable development, and notes that she gets requests from companies outside the fashion industry.

Over in San Diego, California, the startup Algenesis has been using algae oil as a replacement for petroleum. The two first products launched by the startup, whose founders are all surfers, are a surfboard and flip flops made from an algal biopolymer that is biodegradable.

In addition to fashion, algae can also be used to produce sustainable alternatives to everyday petrochemical products. For example, the startup Living Ink, in the US, aims to provide an eco-friendly alternative to printing ink using cyanobacteria.

After some initial hiccups, algae seem to be finding their way into the market. The new generation of startups in this field focus more on business-to-business relationships but build their branding around customers demand for environmentally friendly products.

It seems clear that cyanobacteria and algae will not replace bacteria and yeast as fermentation organisms in traditional applications. However, they have unique characteristics and a potential waiting to be unlocked by more research and daring business ideas. I cannot see limitations to what can be done with algae, but our own imagination, noted Crozet.

Cover illustration by Elena Resko, pictures courtesy of AlgaEnergy and AlgaLife

Go here to see the original:
After Years of Neglect, Algae Biotechnology Makes a... - Labiotech.eu

Global Food Biotechnology Industry 2020 Market Research Reportis an in depth study providing complete analysis of the Food Biotechnology Market for the period 20202025. It provides complete overview of market size, share, growth, trends, industry chain structure, top manufacturers Food Biotechnology market dynamics and competitive scenario.

Get Sample Copy athttps://www.orianresearch.com/request-sample/1515419

Product Type Coverage (Market Size & Forecast, Major Company of Product Type etc.

Development policies and plansare discussed as well as manufacturing processes and cost structures. This report also states import/export, supply and consumption figures as well as cost, price, revenue and gross margin by regions North America, Europe, Japan, China, and other regions (India, Southeast Asia, Central & South America, and Middle East & Africa) and other regions can be added.

GlobalFood Biotechnology Marketreport has been compiled through extensive primary research (through analytical research, market survey and observations) and secondary research. The report also features a complete qualitative and quantitative assessment by analyzing data gathered from industry analysts and market participants across key points in the industrys value chain.

Key Companies Analyzed in this Report are:

ABS Global

Arcadia Biosciences

AquaBounty Technologies

BASF Plant Science

Bayer CropScience AG

Camson Bio Technologies Ltd

Dow AgroSciences LLC

DuPont Pioneer

Evogene Ltd

Hy-Line International

KWS Group

Monsanto

Origin Agritech Limited

Syngenta AG

Application Coverage (Market Size & Forecast, Different Demand Market by Region, Main Consumer Profile etc.):

Animals

Plants

Others

Place a Direct Order Of this Report @https://www.orianresearch.com/checkout/1515419

Major Points Covered in Table of Contents:1 Industry Overview

2 Industry Environment (PEST Analysis)

3 Food Biotechnology Market by Type

4 Major Companies List

5 Market Competition

6 Demand by End Market

7 Region Operation

8 Marketing & Price

9 Research Conclusion

About Us

Orian Research is one of the most comprehensive collections of market intelligence reports on The World Wide Web. Our reports repository boasts of over 500000+ industry and country research reports from over 100 top publishers. We continuously update our repository so as to provide our clients easy access to the worlds most complete and current database of expert insights on global industries, companies, and products. We also specialize in custom research in situations where our syndicate research offerings do not meet the specific requirements of our esteemed clients.

Contact Us

Ruwin Mendez

Vice President Global Sales & Partner Relations

Orian Research Consultants

US: +1 (832) 380-8827 | UK: +44 0161-818-8027

Email:[emailprotected]

Continue reading here:
Food Biotechnology Industry Growth, Regional Trends, Top Manufacturers, Share and 2020-2025 Forecast - The News Brok

DGAP-News: B.R.A.I.N. Biotechnology Research And Information Network AG / Key word(s): Quarter Results/Quarterly / Interim StatementB.R.A.I.N. Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

31.08.2020 / 08:30 The issuer is solely responsible for the content of this announcement.

BRAIN is pleased with its results for the first nine months of the 2019/20 financial year

Zwingenberg, Germany31 August 2020

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG, ISIN DE0005203947 / WKN 520394) today published its results for the first nine months of the 2019/20 financial year. Accordingly, the BRAIN Group reports revenues of ? 29.6 million compared to ? 27.9 million in the same period of the previous year. Taking into account the deconsolidation of Monteil Cosmetics GmbH, this corresponds to organic growth of 12.2%.

Third quarter revenues increased by 8.4% to ? 9.6 million from ? 8.9 million in the same period last year. This growth was purely organic, achieved in both the BioScience and BioIndustrial segments.

"Particularly considering the general economic situation, we have achieved very good growth," says Manfred Bender, CFO of BRAIN AG. "The fact that this growth is more pronounced in our research-driven segment is again due to the higher business volume with existing customers as well as new contracts for tailormade solutions projects."

Development by segments

The BioScience segment generated revenues of ? 10.5 million in the reporting period, up 37.5% from the prior-year period. Adjusted EBITDA improved from ? -4.4 million to ? -3.1 million.

Revenues of the BioIndustrial segment, which is related to product sales, decreased by 5.9% from ? 20.3 million to ? 19.1 million in the reporting period. Organically, revenues here increased by ? 0.4 million or 2.1% from ? 18.7 million to ? 19.1 million. The adjusted EBITDA of the segment developed positively and increased by 9.2% from ? 2.3 million to ? 2.6 million. This corresponds to an adjusted EBITDA margin of 13.3% compared to 11.5% in the previous year.

The reasons for the weaker revenue growth in the product business are, in addition to the start of new production facilities in Cardiff (UK) and Bttelborn, the globally reduced demand for bioethanol and alcoholic beverages due to the Corona pandemic. The BRAIN subsidiary WeissBioTech supplies, among others, powerful enzymes to bioethanol producers and the wine industry.

Despite the ongoing Corona virus pandemic and the associated economic uncertainty, BRAIN AG is still confident to make further progress in the projected direction, albeit possibly at a slightly slower pace.

Key financials (first nine months of fiscal year 2019/20)

More detailed information on the financial results are available at http://www.brain-biotech.com/investors/financial-publications as part of the quarterly statement for the period ended 30 June 2020.

Financial Calendar:

http://www.brain-biotech.com/investors/financial-calendar

About BRAIN

B.R.A.I.N. Biotechnology Research and Information Network AG (BRAIN AG; ISIN DE0005203947 / WKN 520394) is one of Europe's leading technology companies in the field of industrial biotechnology, the core discipline of the bioeconomy. As such, BRAIN identifies previously untapped efficient enzymes, microbial producer organisms or natural substances from complex biological systems that can be put to industrial use. The innovative solutions and products developed by means of "Nature's Toolbox" are successfully applied in the chemicals, cosmetics and food industries.

BRAIN's business model is based on two pillars. The BioScience segment mainly comprises research and development business with industrial partners ("Tailor-Made Solutions" cooperation business), and the company's own research and development. The BioIndustrial segment consists mainly of business with industrially scalable products.

B.R.A.I.N.Biotechnology ResearchAnd Information Network AGDarmstdter Str. 34-3664673 ZwingenbergGermanywww.brain-biotech.com

Contact Investor RelationsMichael SchneidersPhone: +49-6251-9331-86Email: mis@brain-biotech.com

Contact MediaDr. Stephanie KonlePhone: +49-(0)-6251-9331-70Email: stk@brain-biotech.com

Disclaimer

This press release contains forward-looking statements. These statements reflect the current views, expectations, and assumptions of the management of BRAIN AG and are based on information currently available to the management. Forward-looking statements are no guarantees of future performance and involve known and unknown risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. There are numerous factors which could influence the future performance by and future developments at BRAIN AG and the BRAIN group of companies. Such factors include, but are not limited to, changes in the general economic and competitive environment, risks associated with capital markets, currency exchange rate fluctuations, changes in international and national laws and regulations, in particular with respect to tax laws and regulations, and other factors. BRAIN AG does not undertake any obligation to update or revise any forward-looking statements.

Follow BRAIN AG on Twitter (Twitter@BRAINbiotech) and LinkedIn (@BRAIN AG)

31.08.2020 Dissemination of a Corporate News, transmitted by DGAP - a service of EQS Group AG.The issuer is solely responsible for the content of this announcement.

The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at http://www.dgap.de

Continue reading here:
BRAIN Biotechnology Research And Information Network AG: BRAIN is pleased with its results for the first nine months of the 2019/20 financial year -...

The 39 rating InvestorsObserver gives to Menlo Therapeutics Inc (MNLO) stock puts it near the bottom of the Biotechnology industry. In addition to scoring higher than 29 percent of stocks in the Biotechnology industry, MNLOs 39 overall rating means the stock scores better than 39 percent of all stocks.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 39 would rank higher than 39 percent of all stocks.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Menlo Therapeutics Inc (MNLO) stock has risen 4.73% while the S&P 500 is lower by -0.03% as of 3:12 PM on Monday, Aug 31. MNLO is up $0.07 from the previous closing price of $1.48 on volume of 1,790,999 shares. Over the past year the S&P 500 has gained 20.67% while MNLO is lower by -67.98%. MNLO lost -$3.75 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Menlo Therapeutics Inc click here.

Read more from the original source:
Is Menlo Therapeutics Inc (MNLO) a Winner in the Biotechnology Industry? - InvestorsObserver

Iovance Biotherapeutics Inc (IOVA) is near the middle in its industry group according to InvestorsObserver. IOVA gets an overall rating of 51. That means it scores higher than 51 percent of stocks. Iovance Biotherapeutics Inc gets a 53 rank in the Biotechnology industry. Biotechnology is number 23 out of 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Iovance Biotherapeutics Inc (IOVA) stock is higher by 4.39% while the S&P 500 has fallen -0.08% as of 11:20 AM on Monday, Aug 31. IOVA has risen $1.39 from the previous closing price of $31.68 on volume of 584,032 shares. Over the past year the S&P 500 is up 20.60% while IOVA has risen 63.15%. IOVA lost -$1.93 per share the over the last 12 months.

To see InvestorsObserver's Sentiment Score for Iovance Biotherapeutics Inc click here.

More:
Is Iovance Biotherapeutics Inc (IOVA) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

The 63 rating InvestorsObserver gives to Heat Biologics Inc (HTBX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 77 percent of stocks in the Biotechnology industry, HTBXs 63 overall rating means the stock scores better than 63 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Heat Biologics Inc (HTBX) stock is trading at $1.26 as of 9:52 AM on Monday, Aug 31, a decline of -$0.08, or -5.97% from the previous closing price of $1.34. The stock has traded between $1.25 and $1.36 so far today. Volume today is below average. So far 1,467,087 shares have traded compared to average volume of 35,406,604 shares.

To see InvestorsObserver's Sentiment Score for Heat Biologics Inc click here.

Read the original here:
Is Heat Biologics Inc (HTBX) Stock Near the Top of the Biotechnology Industry? - InvestorsObserver

TheGlobal Agricultural Biotechnology Market To Gain Massive Profits During Projected TimespanA fundamental outline of theAgricultural Biotechnology Marketniche is presented by the Agricultural Biotechnology Market report that entails definitions, classifications, applications together with industry chain framework. TheAgricultural Biotechnology Marketreport provides a far-reaching evaluation of necessary market dynamics and the latest trends. It also highlights the regional market, the prominent market players, as well as several market segments [Product, Applications, End-Users, and Major Regions], and sub-segments with a wide-ranging consideration of numerous divisions with their applications.

Request Free Sample Report of Agricultural Biotechnology Market Report @https://www.zionmarketresearch.com/sample/agricultural-biotechnology-market

Our Free Complimentary Sample Report Accommodate a Brief Introduction of the research report, TOC, List of Tables and Figures, Competitive Landscape and Geographic Segmentation, Innovation and Future Developments Based on Research Methodology

Some of the Major Market Players Are:

Monsanto, Vilmorin, Bayer CropScience, Syngenta, Certis, DuPont Pioneer Hi-Bred, Evogene, KWS SAAT, Dow AgroSciences

Further, the report acknowledges that in these growing and promptly enhancing market circumstances, the most recent advertising and marketing details are very important to determine the performance in the forecast period and make essential choices for profitability and growth of the Agricultural Biotechnology Market. In addition, the report encompasses an array of factors that impact the growth of the Agricultural Biotechnology Market in the forecast period. Further, this specific analysis also determines the impact on the individual segments of the market.

Furthermore, the study assessed major market elements, covering the cost, capacity utilization rate, growth rate, capacity, production, gross, usage, revenue, export, supply, price, market share, gross margin, import, and demand. In addition, the study offers a thorough segmentation of the global Agricultural Biotechnology Market on the basis of geography [ Latin America, North America, Asia Pacific, Middle & East Africa, and Europe] , technology, end-users, applications, and region.

Download Free PDF Report Brochure@https://www.zionmarketresearch.com/requestbrochure/agricultural-biotechnology-market

The Agricultural Biotechnology Market report is a collection of pragmatic information, quantitative and qualitative estimation by industry experts, the contribution from industry connoisseurs and industry accomplices across the value chain. Furthermore, the report also provides the qualitative results of diverse market factors on its geographies and segments.

The Agricultural Biotechnology Market report is an appropriate compilation of all necessary data for the residential, industrial. & commercials buyers, manufacturers, governments, and other stakeholders to implement their market-centric tactics in line with the projected as well as the prevailing trends in the Agricultural Biotechnology Market. Apart from this, the report also provides insightful particulars of the existing policies, laws, together with guidelines.

Inquire more about this report @https://www.zionmarketresearch.com/inquiry/agricultural-biotechnology-market

Promising Regions & Countries Mentioned In The Agricultural Biotechnology Market Report:

Chapters Covered in Research Report are :

Chapter 1,2 :The goal of global Agricultural Biotechnology Market covering the market introduction, product image, market summary and development scope.

Chapter 3, 4 :Global Market Competitions by Manufacturers, Sales Volume and Market Profit.

Chapter 5,6,7:Global Supply (Production), Consumption, Export, Import by Regions like United States, Asia-Pacific, China, India, Japan. Conducts the region-wise study of the market based on the sales ratio in each region, and market share from 2015 to 2024

Chapter 8,9,10:Global Market Analysis by Application, Cost Analysis, Marketing Strategy Analysis, Distributors/Traders

Chapter 11,12 :Market information and study conclusions, appendix and data sources.

The market report also identifies further useful and usable information about the industry mainly includes Agricultural Biotechnology Market development trend analysis, investment return and feasibility analysis. Further, SWOT analysis is deployed in the report to analyze the key global market players growth in the Agricultural Biotechnology Market industry

Purposes Behind Buying Agricultural Biotechnology Market Report:-

Key questions answered in this comprehensive study Global Agricultural Biotechnology Market Size, Status and Forecast 2026

Request the coronavirus impact analysis across industries and market

Request impact analysis on this markethttps://www.zionmarketresearch.com/custom/8?covid19=true

Also, Research Report Examines:

Thanks for reading this article; you can also get individual chapter wise section or region wise report version like North America, Europe or Asia.

View original post here:
Global Agricultural Biotechnology Market To Gain Massive Profits During Projected Timespan - Galus Australis

BEDFORD, N.H., Aug. 27, 2020 /PRNewswire/ --LSNE Contract Manufacturing, a leading contract development and manufacturing organization, is pleased to announce that the Spanish Agency of Medicines and Medical Devices (AEMPS) has approved the manufacturing of clinical stage biotechnology based therapeutic products at its aseptic fill finish facility in Len, Spain. This important approval builds upon LSNE's well-established capabilities in providing aseptic fill finish of biologic products for clients at its US facilities. These products include monoclonal antibodies, fusion proteins, replacement enzymes, plasmids, capsids, and oligonucleotides.

"The authorization of biologic manufacturing for clinical drug product in both vial and pre-filled syringe (PFS) presentations is a vital step to our maturation of drug product manufacturing at our facility in Spain. This will provide the global market with more access to LSNE facilities for the manufacture of these high-value biologics, including monoclonal antibodies and other recombinant proteins," said Shawn Cain, LSNE's Chief Operating Officer.

Jaime Del Campo, Site Head at LSNE-Len said, "We are thrilled with this most recent milestone and our ongoing partnership with AEMPS. This is another big step forward supported by our industry leading quality and operations teams. We anticipate this authorization will have an immediate impact in our ability to support our client's varied clinical programs and ensures long-term benefits to their future commercial supply."

About LSNE

LSNE is a privately held company with six GMP facilities four located in New Hampshire, one in Wisconsin and one located in Len, Spain. LSNE has been providing contract lyophilization services to the pharmaceutical, biotechnology, and medical device industries since 1997, specializing in a wide range of services including process cycle development, fill-finish and lyophilization (for vials, pre-filled syringes and dropper bottles for ophthalmics), and analytical testing. Through the thoughtful integration of six processing facilities, qualified staffing, and extensive manufacturing history, LSNE is strategically positioned to provide products and services for clinical through commercial supply for pharmaceuticals and medical devices to a global market.

Media Contact

Jeff ClementVice President of Business Development(603) 668-5763info@lyophilization.comwww.lyophilization.com

View original content to download multimedia:http://www.prnewswire.com/news-releases/lsne-leon-receives-approval-from-aemps-to-manufacture-biotechnology-based-therapeutic-products-301119798.html

SOURCE LSNE Contract Manufacturing

Link:
LSNE-Len Receives Approval From AEMPS To Manufacture Biotechnology Based Therapeutic Products - BioSpace

Albendazole Veterinary Drug Market Los Angeles, United State,, The global Albendazole Veterinary Drug market is expected to surge at a steady CAGR in the coming years, states the latest QY Research report. The publication offers an insightful take on the historical data of the market and the milestones it has achieved. The report also includes an assessment of current market trends and dynamics, which helps in mapping the trajectory of the global Albendazole Veterinary Drug market. Analysts have used Porters five forces analysis and SWOT analysis to explain the various elements of the market in absolute detail. Furthermore, it also studies the socio-economic factors, political changes, and environmental norms that are likely to affect the global Albendazole Veterinary Drug market.

The research report is committed to giving its readers an unbiased point of view of the global Albendazole Veterinary Drug market. Thus, along with statistics, it includes opinions and recommendation of market experts. This allows the readers to acquire a holistic view of the global market and the segments therein. The research report includes the study of the market segments on the basis of type, application, and region. This helps in identifying segment-specific drivers, restraints, threats, and opportunities.

Get PDF template of this report: https://www.qyresearch.com/sample-form/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

The following Companies as the Key Players in the Global Albendazole Veterinary Drug Market Research Report:

, GSK, Sequent Scientific, Zoetis, AdvaCare Pharma, Guangdong Tianbao Biological Pharmaceutical Co., Ltd., Hanzhonghe Times Biotechnology Co., Ltd., Yahui Medicine, Beijing Shengmu Biotechnology Co., Ltd., Hebei Huabang Biological Technology Co., Ltd., Dongguan Meidehao Animal Pharmaceutical Co., Ltd., Sichuan Jinfeng Technology, Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd., Anhui Shenhui Agricultural Technology Co., Ltd., Foshan Zhengdian Biotechnology Co., Ltd., Shanghai Shenya, Tianjin Bijia Pharmaceutical Co., Ltd., Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province, Shimu Group, CSTP, Sneha Medicare Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Product Type Segments

, Capsule Product, Table Product Albendazole Veterinary Drug

Albendazole Veterinary Drug Market Application Segments?<

Swine, Cattle, Others

Regions Covered in the Global Albendazole Veterinary Drug Market:

The Middle East and Africa (GCC Countries and Egypt) North America (the United States, Mexico, and Canada) South America (Brazil etc.) Europe (Turkey, Germany, Russia UK, Italy, France, etc.) Asia-Pacific (Vietnam, China, Malaysia, Japan, Philippines, Korea, Thailand, India, Indonesia, and Australia)

The scope of the Report:

The research report on the global Albendazole Veterinary Drug market is a comprehensive publication that aims to identify the financial outlook of the market. For the same reason, it offers a detailed understanding of the competitive landscape. It studies some of the leading players, their management styles, their research and development statuses, and their expansion strategies.The report also includes product portfolios and the list of products in the pipeline. It includes a thorough explanation of the cutting-edging technologies and investments being made to upgrade the existing ones.

Enquire for customization in Report @https://www.qyresearch.com/customize-request/form/1702061/covid-19-impact-on-global-albendazole-veterinary-drug-market

Strategic Points Covered in TOC:

1 Study Coverage 1.1 Albendazole Veterinary Drug Product Introduction 1.2 Market Segments 1.3 Key Albendazole Veterinary Drug Manufacturers Covered: Ranking by Revenue 1.4 Market by Type1.4.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Type1.4.2 Capsule Product1.4.3 Table Product 1.5 Market by Application1.5.1 Global Albendazole Veterinary Drug Market Size Growth Rate by Application1.5.2 Swine1.5.3 Cattle1.5.4 Others 1.6 Coronavirus Disease 2019 (Covid-19): Albendazole Veterinary Drug Industry Impact1.6.1 How the Covid-19 is Affecting the Albendazole Veterinary Drug Industry

1.6.1.1 Albendazole Veterinary Drug Business Impact Assessment Covid-19

1.6.1.2 Supply Chain Challenges

1.6.1.3 COVID-19s Impact On Crude Oil and Refined Products1.6.2 Market Trends and Albendazole Veterinary Drug Potential Opportunities in the COVID-19 Landscape1.6.3 Measures / Proposal against Covid-19

1.6.3.1 Government Measures to Combat Covid-19 Impact

1.6.3.2 Proposal for Albendazole Veterinary Drug Players to Combat Covid-19 Impact 1.7 Study Objectives 1.8 Years Considered 2 Executive Summary 2.1 Global Albendazole Veterinary Drug Market Size Estimates and Forecasts2.1.1 Global Albendazole Veterinary Drug Revenue 2015-20262.1.2 Global Albendazole Veterinary Drug Sales 2015-2026 2.2 Albendazole Veterinary Drug Market Size by Region: 2020 Versus 20262.2.1 Global Albendazole Veterinary Drug Retrospective Market Scenario in Sales by Region: 2015-20202.2.2 Global Albendazole Veterinary Drug Retrospective Market Scenario in Revenue by Region: 2015-2020 3 Global Albendazole Veterinary Drug Competitor Landscape by Players 3.1 Albendazole Veterinary Drug Sales by Manufacturers3.1.1 Albendazole Veterinary Drug Sales by Manufacturers (2015-2020)3.1.2 Albendazole Veterinary Drug Sales Market Share by Manufacturers (2015-2020) 3.2 Albendazole Veterinary Drug Revenue by Manufacturers3.2.1 Albendazole Veterinary Drug Revenue by Manufacturers (2015-2020)3.2.2 Albendazole Veterinary Drug Revenue Share by Manufacturers (2015-2020)3.2.3 Global Albendazole Veterinary Drug Market Concentration Ratio (CR5 and HHI) (2015-2020)3.2.4 Global Top 10 and Top 5 Companies by Albendazole Veterinary Drug Revenue in 20193.2.5 Global Albendazole Veterinary Drug Market Share by Company Type (Tier 1, Tier 2 and Tier 3) 3.3 Albendazole Veterinary Drug Price by Manufacturers 3.4 Albendazole Veterinary Drug Manufacturing Base Distribution, Product Types3.4.1 Albendazole Veterinary Drug Manufacturers Manufacturing Base Distribution, Headquarters3.4.2 Manufacturers Albendazole Veterinary Drug Product Type3.4.3 Date of International Manufacturers Enter into Albendazole Veterinary Drug Market 3.5 Manufacturers Mergers & Acquisitions, Expansion Plans 4 Breakdown Data by Type (2015-2026) 4.1 Global Albendazole Veterinary Drug Market Size by Type (2015-2020)4.1.1 Global Albendazole Veterinary Drug Sales by Type (2015-2020)4.1.2 Global Albendazole Veterinary Drug Revenue by Type (2015-2020)4.1.3 Albendazole Veterinary Drug Average Selling Price (ASP) by Type (2015-2026) 4.2 Global Albendazole Veterinary Drug Market Size Forecast by Type (2021-2026)4.2.1 Global Albendazole Veterinary Drug Sales Forecast by Type (2021-2026)4.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Type (2021-2026)4.2.3 Albendazole Veterinary Drug Average Selling Price (ASP) Forecast by Type (2021-2026) 4.3 Global Albendazole Veterinary Drug Market Share by Price Tier (2015-2020): Low-End, Mid-Range and High-End 5 Breakdown Data by Application (2015-2026) 5.1 Global Albendazole Veterinary Drug Market Size by Application (2015-2020)5.1.1 Global Albendazole Veterinary Drug Sales by Application (2015-2020)5.1.2 Global Albendazole Veterinary Drug Revenue by Application (2015-2020)5.1.3 Albendazole Veterinary Drug Price by Application (2015-2020) 5.2 Albendazole Veterinary Drug Market Size Forecast by Application (2021-2026)5.2.1 Global Albendazole Veterinary Drug Sales Forecast by Application (2021-2026)5.2.2 Global Albendazole Veterinary Drug Revenue Forecast by Application (2021-2026)5.2.3 Global Albendazole Veterinary Drug Price Forecast by Application (2021-2026) 6 North America 6.1 North America Albendazole Veterinary Drug by Country6.1.1 North America Albendazole Veterinary Drug Sales by Country6.1.2 North America Albendazole Veterinary Drug Revenue by Country6.1.3 U.S.6.1.4 Canada 6.2 North America Albendazole Veterinary Drug Market Facts & Figures by Type 6.3 North America Albendazole Veterinary Drug Market Facts & Figures by Application 7 Europe 7.1 Europe Albendazole Veterinary Drug by Country7.1.1 Europe Albendazole Veterinary Drug Sales by Country7.1.2 Europe Albendazole Veterinary Drug Revenue by Country7.1.3 Germany7.1.4 France7.1.5 U.K.7.1.6 Italy7.1.7 Russia 7.2 Europe Albendazole Veterinary Drug Market Facts & Figures by Type 7.3 Europe Albendazole Veterinary Drug Market Facts & Figures by Application 8 Asia Pacific 8.1 Asia Pacific Albendazole Veterinary Drug by Region8.1.1 Asia Pacific Albendazole Veterinary Drug Sales by Region8.1.2 Asia Pacific Albendazole Veterinary Drug Revenue by Region8.1.3 China8.1.4 Japan8.1.5 South Korea8.1.6 India8.1.7 Australia8.1.8 Taiwan8.1.9 Indonesia8.1.10 Thailand8.1.11 Malaysia8.1.12 Philippines8.1.13 Vietnam 8.2 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Type 8.3 Asia Pacific Albendazole Veterinary Drug Market Facts & Figures by Application 9 Latin America 9.1 Latin America Albendazole Veterinary Drug by Country9.1.1 Latin America Albendazole Veterinary Drug Sales by Country9.1.2 Latin America Albendazole Veterinary Drug Revenue by Country9.1.3 Mexico9.1.4 Brazil9.1.5 Argentina 9.2 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Type 9.3 Central & South America Albendazole Veterinary Drug Market Facts & Figures by Application 10 Middle East and Africa 10.1 Middle East and Africa Albendazole Veterinary Drug by Country10.1.1 Middle East and Africa Albendazole Veterinary Drug Sales by Country10.1.2 Middle East and Africa Albendazole Veterinary Drug Revenue by Country10.1.3 Turkey10.1.4 Saudi Arabia10.1.5 UAE 10.2 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Type 10.3 Middle East and Africa Albendazole Veterinary Drug Market Facts & Figures by Application 11 Company Profiles 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.2 Sequent Scientific11.2.1 Sequent Scientific Corporation Information11.2.2 Sequent Scientific Description, Business Overview and Total Revenue11.2.3 Sequent Scientific Sales, Revenue and Gross Margin (2015-2020)11.2.4 Sequent Scientific Albendazole Veterinary Drug Products Offered11.2.5 Sequent Scientific Recent Development 11.3 Zoetis11.3.1 Zoetis Corporation Information11.3.2 Zoetis Description, Business Overview and Total Revenue11.3.3 Zoetis Sales, Revenue and Gross Margin (2015-2020)11.3.4 Zoetis Albendazole Veterinary Drug Products Offered11.3.5 Zoetis Recent Development 11.4 AdvaCare Pharma11.4.1 AdvaCare Pharma Corporation Information11.4.2 AdvaCare Pharma Description, Business Overview and Total Revenue11.4.3 AdvaCare Pharma Sales, Revenue and Gross Margin (2015-2020)11.4.4 AdvaCare Pharma Albendazole Veterinary Drug Products Offered11.4.5 AdvaCare Pharma Recent Development 11.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd.11.5.1 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Corporation Information11.5.2 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.5.3 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.5.4 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.5.5 Guangdong Tianbao Biological Pharmaceutical Co., Ltd. Recent Development 11.6 Hanzhonghe Times Biotechnology Co., Ltd.11.6.1 Hanzhonghe Times Biotechnology Co., Ltd. Corporation Information11.6.2 Hanzhonghe Times Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.6.3 Hanzhonghe Times Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.6.4 Hanzhonghe Times Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.6.5 Hanzhonghe Times Biotechnology Co., Ltd. Recent Development 11.7 Yahui Medicine11.7.1 Yahui Medicine Corporation Information11.7.2 Yahui Medicine Description, Business Overview and Total Revenue11.7.3 Yahui Medicine Sales, Revenue and Gross Margin (2015-2020)11.7.4 Yahui Medicine Albendazole Veterinary Drug Products Offered11.7.5 Yahui Medicine Recent Development 11.8 Beijing Shengmu Biotechnology Co., Ltd.11.8.1 Beijing Shengmu Biotechnology Co., Ltd. Corporation Information11.8.2 Beijing Shengmu Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.8.3 Beijing Shengmu Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.8.4 Beijing Shengmu Biotechnology Co., Ltd. Albendazole Veterinary Drug Products Offered11.8.5 Beijing Shengmu Biotechnology Co., Ltd. Recent Development 11.9 Hebei Huabang Biological Technology Co., Ltd.11.9.1 Hebei Huabang Biological Technology Co., Ltd. Corporation Information11.9.2 Hebei Huabang Biological Technology Co., Ltd. Description, Business Overview and Total Revenue11.9.3 Hebei Huabang Biological Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.9.4 Hebei Huabang Biological Technology Co., Ltd. Albendazole Veterinary Drug Products Offered11.9.5 Hebei Huabang Biological Technology Co., Ltd. Recent Development 11.10 Dongguan Meidehao Animal Pharmaceutical Co., Ltd.11.10.1 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Corporation Information11.10.2 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.10.3 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.10.4 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Albendazole Veterinary Drug Products Offered11.10.5 Dongguan Meidehao Animal Pharmaceutical Co., Ltd. Recent Development 11.1 GSK11.1.1 GSK Corporation Information11.1.2 GSK Description, Business Overview and Total Revenue11.1.3 GSK Sales, Revenue and Gross Margin (2015-2020)11.1.4 GSK Albendazole Veterinary Drug Products Offered11.1.5 GSK Recent Development 11.12 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd.11.12.1 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Corporation Information11.12.2 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.12.3 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.12.4 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Products Offered11.12.5 Shijiazhuang Jinding Animal Pharmaceutical Co., Ltd. Recent Development 11.13 Anhui Shenhui Agricultural Technology Co., Ltd.11.13.1 Anhui Shenhui Agricultural Technology Co., Ltd. Corporation Information11.13.2 Anhui Shenhui Agricultural Technology Co., Ltd. Description, Business Overview and Total Revenue11.13.3 Anhui Shenhui Agricultural Technology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.13.4 Anhui Shenhui Agricultural Technology Co., Ltd. Products Offered11.13.5 Anhui Shenhui Agricultural Technology Co., Ltd. Recent Development 11.14 Foshan Zhengdian Biotechnology Co., Ltd.11.14.1 Foshan Zhengdian Biotechnology Co., Ltd. Corporation Information11.14.2 Foshan Zhengdian Biotechnology Co., Ltd. Description, Business Overview and Total Revenue11.14.3 Foshan Zhengdian Biotechnology Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.14.4 Foshan Zhengdian Biotechnology Co., Ltd. Products Offered11.14.5 Foshan Zhengdian Biotechnology Co., Ltd. Recent Development 11.15 Shanghai Shenya11.15.1 Shanghai Shenya Corporation Information11.15.2 Shanghai Shenya Description, Business Overview and Total Revenue11.15.3 Shanghai Shenya Sales, Revenue and Gross Margin (2015-2020)11.15.4 Shanghai Shenya Products Offered11.15.5 Shanghai Shenya Recent Development 11.16 Tianjin Bijia Pharmaceutical Co., Ltd.11.16.1 Tianjin Bijia Pharmaceutical Co., Ltd. Corporation Information11.16.2 Tianjin Bijia Pharmaceutical Co., Ltd. Description, Business Overview and Total Revenue11.16.3 Tianjin Bijia Pharmaceutical Co., Ltd. Sales, Revenue and Gross Margin (2015-2020)11.16.4 Tianjin Bijia Pharmaceutical Co., Ltd. Products Offered11.16.5 Tianjin Bijia Pharmaceutical Co., Ltd. Recent Development 11.17 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province11.17.1 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Corporation Information11.17.2 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Description, Business Overview and Total Revenue11.17.3 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Sales, Revenue and Gross Margin (2015-2020)11.17.4 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Products Offered11.17.5 Tianyuan Animal Medicine, Hanzhong City, Shaanxi Province Recent Development 11.18 Shimu Group11.18.1 Shimu Group Corporation Information11.18.2 Shimu Group Description, Business Overview and Total Revenue11.18.3 Shimu Group Sales, Revenue and Gross Margin (2015-2020)11.18.4 Shimu Group Products Offered11.18.5 Shimu Group Recent Development 11.19 CSTP11.19.1 CSTP Corporation Information11.19.2 CSTP Description, Business Overview and Total Revenue11.19.3 CSTP Sales, Revenue and Gross Margin (2015-2020)11.19.4 CSTP Products Offered11.19.5 CSTP Recent Development 11.20 Sneha Medicare11.20.1 Sneha Medicare Corporation Information11.20.2 Sneha Medicare Description, Business Overview and Total Revenue11.20.3 Sneha Medicare Sales, Revenue and Gross Margin (2015-2020)11.20.4 Sneha Medicare Products Offered11.20.5 Sneha Medicare Recent Development 12 Future Forecast by Regions (Countries) (2021-2026) 12.1 Albendazole Veterinary Drug Market Estimates and Projections by Region12.1.1 Global Albendazole Veterinary Drug Sales Forecast by Regions 2021-202612.1.2 Global Albendazole Veterinary Drug Revenue Forecast by Regions 2021-2026 12.2 North America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.2.1 North America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.2.2 North America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.2.3 North America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.3 Europe Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.3.1 Europe: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.3.2 Europe: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.3.3 Europe: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.4 Asia Pacific Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.4.1 Asia Pacific: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.4.2 Asia Pacific: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.4.3 Asia Pacific: Albendazole Veterinary Drug Market Size Forecast by Region (2021-2026) 12.5 Latin America Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.5.1 Latin America: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.5.2 Latin America: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.5.3 Latin America: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 12.6 Middle East and Africa Albendazole Veterinary Drug Market Size Forecast (2021-2026)12.6.1 Middle East and Africa: Albendazole Veterinary Drug Sales Forecast (2021-2026)12.6.2 Middle East and Africa: Albendazole Veterinary Drug Revenue Forecast (2021-2026)12.6.3 Middle East and Africa: Albendazole Veterinary Drug Market Size Forecast by Country (2021-2026) 13 Market Opportunities, Challenges, Risks and Influences Factors Analysis 13.1 Market Opportunities and Drivers 13.2 Market Challenges 13.3 Market Risks/Restraints 13.4 Porters Five Forces Analysis 13.5 Primary Interviews with Key Albendazole Veterinary Drug Players (Opinion Leaders) 14 Value Chain and Sales Channels Analysis 14.1 Value Chain Analysis 14.2 Albendazole Veterinary Drug Customers 14.3 Sales Channels Analysis14.3.1 Sales Channels14.3.2 Distributors 15 Research Findings and Conclusion 16 Appendix 16.1 Research Methodology16.1.1 Methodology/Research Approach16.1.2 Data Source 16.2 Author Details 16.3 Disclaimer

About Us:

QYResearch always pursuits high product quality with the belief that quality is the soul of business. Through years of effort and supports from the huge number of customer supports, QYResearch consulting group has accumulated creative design methods on many high-quality markets investigation and research team with rich experience. Today, QYResearch has become the brand of quality assurance in the consulting industry.

Read more:
Global Albendazole Veterinary Drug Market: Trends, Opportunities, Restraints, Key Manufacturers And Forecast During The Projected Period 2020-2026...

This article was originally published here

Int J Stem Cells. 2020 Aug 31. doi: 10.15283/ijsc20076. Online ahead of print.

ABSTRACT

COVID-19 pandemic has brought the whole world stand still, locked down in their homes, infecting more than 8 million people, and many thousands (449,182) -have lost their lives across the globe. Due to lack of any definitive medicine or vaccine, treatment options are supportive of oxygenation, antiviral, antiretroviral drugs, antibiotics, fluid/ electrolyte, mechanical ventilation with ICU (Intensive Care Unit) support, and chloroquine/hydroxychloroquine have been tried to fight this infection. However, mortality due to severe pneumonia, ARDS (Acute Respiratory Distress Syndrome), and multiorgan failure arising from the overactive immune response (storm) mediated by cytokines remains a treatment challenge in elderly and patients with severe medical comorbidities. Recently, anti-inflammatory, angiogenic, immune-modular, and healing properties of intravenous injections of culture derived stem cells have been proposed and shown to benefits in a small number of patients with severe COVID-19 infections. Based on previous experience with other viral infections, convalescent plasma, and serum transfusion are being used as a source of neutralizing antibody/factors to minimize the effects of inflammatory cytokines in this infection. Immunotherapy with purified monoclonal antibodies and conditioned serum with a mixture of unique cytokines are also being developed. Regenerative Medicine has emerged as a crucial adjuvant tool in promoting healing and early recovery in severe COVID-19 infections and other supportive treatments.

PMID:32840231 | DOI:10.15283/ijsc20076

See the original post here:
Emerging Treatment Options of Regenerative Medicine in Severe Corona Virus/COVID 19 Infections - DocWire News

This article was originally published here

Stem Cells Transl Med. 2020 Aug 27. doi: 10.1002/sctm.20-0245. Online ahead of print.

ABSTRACT

This perspective from a Regenerative Medicine Manufacturing Society working group highlights regenerative medicine therapeutic opportunities for fighting COVID-19. This article addresses why SARS-CoV-2 is so different from other viruses and how regenerative medicine is poised to deliver new therapeutic opportunities to battle COVID-19. We describe animal models that depict the mechanism of action for COVID-19 and that may help identify new treatments. Additionally, organoid platforms that can recapitulate some of the physiological properties of human organ systems, such as the lungs and the heart, are discussed as potential platforms that may prove useful in rapidly screening new drugs and identifying at-risk patients. This article critically evaluates some of the promising regenerative medicine-based therapies for treating COVID-19 and presents some of the collective technologies and resources that the scientific community currently has available to confront this pandemic.

PMID:32856432 | DOI:10.1002/sctm.20-0245

Read more:
Regen med therapeutic opportunities for fighting COVID-19 - DocWire News